Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
—·3h
Its latest fundraising round provides the French biotech with enough cash to finance operations through 2029.
TickersCNBCChannelsstocksCountriesusaCategoriesceo-changes
Open original source ↗Published
7/10/2026, 10:10:15 AM
Fetched
7/10/2026, 12:07:51 PM
Confidence
60 / 100
Relevance
35 / 100
Trust
—
Language
en